Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique

被引:0
|
作者
Bonny Parkinson
Sallie-Anne Pearson
Rosalie Viney
机构
[1] University of Technology,Centre for Health Economics Research and Evaluation (CHERE)
[2] Sydney,Pharmacoepidemiology and Pharmaceutical Policy Research Group, Faculty of Pharmacy
[3] The University of Sydney,undefined
来源
The European Journal of Health Economics | 2014年 / 15卷
关键词
Economics; Cost-utility analysis; Cost-effectiveness analysis; Breast neoplasms; Metastatic; Trastuzumab; I18; D61;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:93 / 112
页数:19
相关论文
共 50 条
  • [21] Trastuzumab beyond progression in HER2-positive metastatic breast cancer
    Al-Naqqash, Manwar
    Jasim Al-Serarati, Waleed
    Farooq Kareem, Tara
    BREAST JOURNAL, 2021, 27 (03): : 297 - 299
  • [22] Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
    Young-A Heo
    Yahiya Y. Syed
    Targeted Oncology, 2019, 14 : 749 - 758
  • [23] Systemic treatment of HER2-positive metastatic breast cancer: A systematic review
    Wilcken, Nicholas
    Zdenkowski, Nicholas
    White, Michelle
    Snyder, Ray
    Pittman, Ken
    Mainwaring, Paul
    Green, Michael
    Francis, Prudence
    De Boer, Richard
    Colosimo, Maree
    Chua, Sue
    Chirgwin, Jacquie
    Beith, Jane
    Bell, Richard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 1 - 14
  • [24] A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer
    Church, David N.
    Price, Chris G. A.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 557 - 570
  • [25] Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of published studies
    Mannocci, Alice
    De Feo, Emma
    de Waurel, Chiara
    Specchia, Maria Lucia
    Gualano, Maria Rosaria
    Barone, Carlo
    Ricciardi, Walter
    La Torre, Giuseppe
    TUMORI JOURNAL, 2010, 96 (03): : 385 - 391
  • [26] Trastuzumab In HER2-Positive Metastatic Gastric Cancer
    Croxtall, Jamie D.
    McKeage, Kate
    DRUGS, 2010, 70 (17) : 2259 - 2267
  • [27] Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer
    Rastogi, Priya
    Davidson, Nancy E.
    ONKOLOGIE, 2010, 33 (8-9): : 420 - 421
  • [28] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
    Paridaens, R., Sr.
    Wildiers, H.
    Dalenc, F.
    Rixe, O.
    Cadic, V.
    Pinel, M.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Biodistribution and pharmacokinetics of radiolabeled trastuzumab in HER2-positive metastatic breast cancer
    Hooge, MNLD
    Perik, PJ
    Gietema, JA
    Jager, PL
    Jonkman, S
    Kosterink, JGW
    Van Veldhuisen, DJJ
    Van der Graaf, WTA
    Sleijfer, DTH
    De Vries, EGE
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 210S - 210S
  • [30] Very long response with trastuzumab for metastatic Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 1002 - 1003